Isis Pharmaceuticals, Inc.

F Andrew Dorr

C Frank Bennett

Nicholas M Dean

Chikateru Nozaki

Kevin P Anderson

Ronnie C Hanecak

T Jesse Kwoh

Jon T Holmlund

Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.

Compositions and methods for treatment of hepatitis C virus-associated diseases

Compositions and methods are provided for the treatment and diagnosis of diseases associated with protein kinase C. Oligonucleotides are provided which are targeted to nucleic acids encoding PKC. In preferred embodiments, the oligonucleotides contain one or more chemical modifications. Methods of modulating PKC expression and of treating animals suffering from disease amenable to therapeutic intervention by modulating protein kinase C expression using oligonucleotides targeted to PKC are disclosed.

Oligonucleotide inhibition of protein kinase C

Growing community of inventors

Solana Beach, CA, United States of America

F Andrew Dorr